Literature DB >> 21263203

Hyperphosphataemia is associated with the diabetes-related cardiovascular risk factors.

Ishtiaq Mahmud1, Zillur Rahman, Shamima Islam Keka, Sudip Devnath, Nuruzzaman Masum, Nuruzzam Masum, Shahdat Hossain.   

Abstract

The serum phosphorus level is recently considered as one of the foretelling markers for the severity of cardiovascular diseases (CVD). We therefore investigated whether the serum phosphorus level in the diabetic patients against healthy individuals could act as a possible marker for identification of vulnerability to cardiovascular disease. One hundred and thirty two human subjects were involved in the study among which one hundred and four subjects are CVD patients and twenty eight were healthy individuals. The levels of the lipid profile and the glycemic status were significantly increased in the patients than those of the control subjects (Fasting glucose, FS=8.3 ± 0.3 vs. 6.1 ± 0.0 mmol/L; blood glucose 2 h after breakfast (STAB)=12.0 ± 0.5 vs. 8.5 ± 0.7, mmol/L; HbA1c (%),6.7 ± 0.2 vs. 5.4 ± 0.3; and Total cholesterol (TC)=189 ± 4.0 vs. 162 ± 7.0; low density lipoprotein cholesterol (LDL-C), 111 ± 3.8 vs. 96 ± 5.0; triacyglycerol (TG), 202 ± 9.0 vs. 118 ± 5.3 mg/dL, respectively. The serum phosphorus level was significantly increased in CVD patients (mg/dL, patient vs. control, 5.1 ± 0.10 vs. 3.7 ± 0.1). Simple regression analyses revealed a highly significant positive correlation between serum phosphorus and TC, TG and FG. Thus the results demonstrate that the serum phosphorus level might be another parameter which is closely associated with diabetes and could also be used as a possible marker for the risk of CVD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21263203     DOI: 10.5650/jos.60.79

Source DB:  PubMed          Journal:  J Oleo Sci        ISSN: 1345-8957            Impact factor:   1.601


  1 in total

1.  High serum phosphate and triglyceride levels in smoking women and men with CVD risk and type 2 diabetes.

Authors:  Lena M Håglin; Birgitta Törnkvist; Lennart O Bäckman
Journal:  Diabetol Metab Syndr       Date:  2014-03-17       Impact factor: 3.320

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.